Non-Invasive Biomarker Strategy Integrating Dd-cfDNA Versus Biopsy-Based Monitoring in Kidney Transplant Recipients | MicrobiomeTrials← Back to trialsNCT04774575
Non-Invasive Biomarker Strategy Integrating Dd-cfDNA Versus Biopsy-Based Monitoring in Kidney Transplant Recipients
CompletedNAINTERVENTIONAL
Trial Details
Start: 2021-12-15Est. Completion: 2024-05-28
Enrollment target: 342 participants Locations- Nantes Hospital, Nantes, France
- Saint-Louis Hospital, Paris, Paris, Île-de-France Region, France
- Necker Hospital, Paris, Paris, Île-de-France Region, France
- Charité-Universitätsmedizin, Berlin, Berlin, Germany
- Charité-Universitätsmedizin,, Berlin, Germany
- Vall d'Hebron Hospital, Barcelona, Spain
- Bellvitge University Hospital, Barcelona, Spain
- Geneva University Hospitals, Geneva, Canton of Geneva, Switzerland
Other microbiome trials you might be interested in
Kidney StonesUrinary Stone Disease / NephrolithiasisRecurrent Calcium-oxalate Kidney Stones
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with…
Park City, United StatesEst. completion Dec 2027
Organic AcidemiaMethylmalonic AcidemiaInborn Errors of Metabolism
Methylmalonic acidemia (MMA), one of the most common inborn errors of organic acid metabolism, is heterogeneous in etiol…
Washington D.C., United States